Entheon Biomedical Corp.

CNSX:ENBI Stock Report

Market Cap: CA$1.5m

Entheon Biomedical Management

Management criteria checks 4/4

Entheon Biomedical's CEO is Timothy Ko, appointed in Jun 2019, has a tenure of 5.5 years. total yearly compensation is CA$75.87K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 2.6% of the company’s shares, worth CA$39.10K. The average tenure of the management team and the board of directors is 3.8 years and 3.8 years respectively.

Key information

Timothy Ko

Chief executive officer

CA$75.9k

Total compensation

CEO salary percentage100.0%
CEO tenure5.5yrs
CEO ownership2.6%
Management average tenure3.8yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Timothy Ko's remuneration changed compared to Entheon Biomedical's earnings?
DateTotal CompensationSalaryCompany Earnings
Aug 31 2024n/an/a

-CA$308k

May 31 2024n/an/a

-CA$338k

Feb 29 2024n/an/a

-CA$279k

Nov 30 2023CA$76kCA$76k

-CA$300k

Aug 31 2023n/an/a

-CA$470k

May 31 2023n/an/a

CA$300k

Feb 28 2023n/an/a

-CA$614k

Nov 30 2022CA$130kCA$130k

-CA$2m

Aug 31 2022n/an/a

-CA$3m

May 31 2022n/an/a

-CA$5m

Feb 28 2022n/an/a

-CA$7m

Nov 30 2021CA$134kCA$134k

-CA$8m

Compensation vs Market: Timothy's total compensation ($USD52.79K) is below average for companies of similar size in the Canadian market ($USD164.07K).

Compensation vs Earnings: Timothy's compensation has been consistent with company performance over the past year.

CEO

Timothy Ko (39 yo)

5.5yrs

Tenure

CA$75,869

Compensation

Mr. Timothy Ko is the Founder of Entheon Holdings Corp. (formerly, Entheon Biomedical Corp. and MPV Exploration Inc.) and has been its Chief Executive Officer since June 2019. Mr. Ko serves as the Presiden...

Leadership Team

NamePositionTenureCompensationOwnership
Timothy Ko
President5.5yrsCA$75.87k2.6%
CA$ 39.1k
Soo-Whan Kim
Interim Chief Financial Officer1.9yrsCA$36.50kno data
Brian Jahns
Chief Business Officer3.8yrsno datano data
Kelly Pladson
Corporate Secretaryno datano datano data

3.8yrs

Average Tenure

Experienced Management: ENBI's management team is considered experienced (3.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Timothy Ko
President4.1yrsCA$75.87k2.6%
CA$ 39.1k
Michael J. Walker
Scientific Advisorno datano datano data
Dennis McKenna
Scientific Advisorno datano datano data
Matthew Johnson
Scientific Advisorno datano datano data
Robin Carhart-Harris
Scientific Advisorno datano datano data
Andrew Hegle
Director4.1yrsCA$89.81k0.11%
CA$ 1.7k
Christopher Gondi
Independent Director4.1yrsCA$12.00k0.56%
CA$ 8.5k
Christopher Timmermann
Scientific Advisorno datano datano data
Nancy Maher
Special Advisor of Data Science & Regulatory Affairs3.8yrsno datano data
Andrew Greenshaw
Scientific Advisor3.4yrsno datano data
David Erritzoe
Scientific Advisor3.3yrsno datano data
Henry Kranzler
Member of Advisory Board3yrsno datano data

3.8yrs

Average Tenure

46yo

Average Age

Experienced Board: ENBI's board of directors are considered experienced (3.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 10:54
End of Day Share Price 2024/12/17 00:00
Earnings2024/08/31
Annual Earnings2023/11/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Entheon Biomedical Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution